



DT11 Rec'd PCT/PTO JUN 14 2002

Dkt. No. 025098-0603

09/807354

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

DERVAN et al.

Title: INHIBITION OF ONCOGENE
TRANSCRIPTION BY SYNTHETIC
POLYAMIDES

Appl. No.: 09/807,354

Filing Date: September 10, 1999

Examiner: V. Alvarado

Int'l App. No. PCT/US99/20489

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on the date below.	
Jodie M. Rivas	
(Printed Name)	
(Signature)	
June 7, 2002	
(Date of Deposit)	

TRANSMITTAL

U.S. Patent and Trademark Office
2011 South Clark Place
Customer Window, Box Sequence
Crystal Plaza Two, Lobby, Room 1B03
Arlington, VA 22202

Sir:

Transmitted herewith is:

- ☒ Notification of Missing Requirements;
- ☒ Sequence Listing Transmittal;
- ☒ Statement to Support Filing and Submission of Sequence Listing;
- ☒ Sequence Listing (Paper Form);
- ☒ Sequence Listing (Computer Readable Form).
- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-0872 (Order No. 025098-0603). Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-0872 (Order No. 025098-0603).

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Respectfully submitted,

Date June 7, 2002
FOLEY & LARDNER
P.O. Box 80278
San Diego, CA 92138-0278
Telephone: (858) 847-6721
Facsimile: (858) 792-6773

By
Michael A. Whittaker
Attorney for Applicant
Registration No. 46,230



PATENT
Attorney Docket No. 025098-0603

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

Date of Deposit: June 7, 2002

I hereby certify that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to the U.S. Patent and Trademark Office, 2011 South Clark Place, Customer Window, Box Sequence, Crystal Plaza Two, Lobby, Room 1B03, Arlington, VA 22202.

Jodie M. Rivas
Printed Name

[Signature]
Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of: Peter B. Dervan

Examiner: V. Alvarado

Serial No.: 09/807,354

Int'l App. No.: PCT/US99/20489

Filing Date: September 10, 2001

For: INHIBITION OF ONCOGENE
TRANSCRIPTION BY SYNTHETIC
POLYAMIDES

SEQUENCE LISTING TRANSMITTAL LETTER

U.S. Patent and Trademark Office
2011 South Clark Place
Customer Window, Box Sequence
Crystal Plaza Two, Lobby, Room 1B03
Arlington, VA 22202

Dear Sir:

In response to the Notification of Missing Requirements mailed May 21, 2002,
enclosed please find the following:

- [X] Copy of Notification of Missing Requirements (4 pages)
- [X] Statement To Support Filing And Submission In Accordance With
7 C.F.R. §§ 1.821-1.825 (2 pages)
- [X] Computer Disk Containing Sequence Listing
- [X] Sequence Listing Paper Copy (4 pages)
- [X] A return postcard.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-0872 (Order No. 025098-0603). Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-0872 (Order No. 025098-0603).

Respectfully submitted,

Date June 7, 2002

FOLEY & LARDNER
P.O. Box 80278
San Diego, California 92138-0278
Telephone: (858) 847-6721
Facsimile: (858) 792-6773

By 

Michael A. Whittaker
Attorney for Applicant
Registration No. 46,230

RECEIVED

MAY 29 2002



UNITED STATES PATENT AND TRADEMARK OFFICE

 Commissioner for Patents - Box PCT
 United States Patent and Trademark Office
 Washington, DC 20591
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/807,354	Peter B Dervan	025098/0603

 Foley & Lardner
 402 W Broadway
 Suite 2300
 San Diego, CA 92101-3542


INTERNATIONAL APPLICATION NO.	
PCT/US99/20489	
I.A. FILING DATE	PRIORITY DATE
09/10/1999	09/11/1998

 CONFIRMATION NO. 6301
 371 FORMALITIES LETTER


OC000000008161678

Date Mailed: 05/21/2002

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fees
- Indication of Small Entity Status
- Priority Document
- Biochemical Sequence Listing
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Oath or Declaration
- Preliminary Amendments
- Request for Immediate Examination
- Small Entity Statement

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTH FROM THE DATE OF THIS NOTICE OR BY 22 or 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

 Due 6-12-02
 Previously Docketed With

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
- APPLICANT MUST PROVIDE:
 - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
 - An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.

- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

WINSTON M ALVARADO

Telephone: (703) 305-6421

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
09/807,354	PCT/US99/20489	025098/0603



13 Received 14 JUN 2002
09/807354

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket No: 025098/0603

In re patent application of

DERVAN, PETER B.

Serial No. 09/807,354

Filed: April 10, 2001

For: INHIBITION OF ONCOGENE TRANSCRIPTION BY SYNTHETIC POLYAMIDES

STATEMENT TO SUPPORT FILING AND SUBMISSION IN
ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825

Assistant Commissioner for Patents
Washington, D.C. 20231
Box SEQUENCE

Sir:

In connection with a Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

1. the submission, filed herewith in accordance with 37 C.F.R. § 1.821(g), does not include new matter;

2. the content of the attached paper copy and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same; and


3. all statements made herein of their own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United

Serial No. 09/807,354

States Code and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Respectfully submitted,

June 6, 2002
Date


James A. Coburn

HARBOR CONSULTING
Intellectual Property Services
1500A Lafayette Road
Suite 262
Portsmouth, N.H.
800-318-3021